title: Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.
abstract: OBJECTIVE
  For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a (188)Re-labelled anti-CD66 monoclonal antibody.
  
  
  METHODS
  For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 +/- 12 years) the residence times were determined for the injected (188)Re-labelled anti-CD66 antibodies (1.3 +/- 0.4 GBq, 5-7 GBq/mg protein, >95% (188)Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i.
  
  
  RESULTS
  The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 +/- 0.2 h, 1.9 +/- 0.8 h, 7.8 +/- 2.1 h, 0.6 +/- 0.3 h and 8.6 +/- 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively.
  
  
  CONCLUSIONS
  The proposed approach allows reliable prediction of biokinetics of (188)Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.
authors.affiliation: Abteilung Nuklearmedizin, Universität Ulm 89070 Ulm, Deutschland. gerhard.glatting@uniklinik-ulm.de
authors.forename: G
authors.initials: G
authors.lastname: Glatting
authors.forename: T
authors.initials: T
authors.lastname: Kull
authors.forename: N M
authors.initials: NM
authors.lastname: Blumstein
authors.forename: D
authors.initials: D
authors.lastname: Bunjes
authors.forename: B
authors.initials: B
authors.lastname: Neumaier
authors.forename: A K
authors.initials: AK
authors.lastname: Buck
authors.forename: S N
authors.initials: SN
authors.lastname: Reske
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D001853:Bone Marrow / Q000000981:diagnostic imaging; D015815:Cell Adhesion Molecules / Q000276:immunology*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007668:Kidney / Q000000981:diagnostic imaging; D007938:Leukemia / Q000000981:diagnostic imaging*; D008099:Liver / Q000000981:diagnostic imaging; D011868:Radioisotopes / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D012211:Rhenium / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity; D013154:Spleen / Q000000981:diagnostic imaging; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D011868:Radioisotopes; D012211:Rhenium